35 filings
Page 2 of 2
8-K
1lb5t8a wasvwq
28 Sep 21
Entry into a Material Definitive Agreement
8:53am
8-K
feneq6y3 h1hu
13 Aug 21
POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update
7:00am
8-K
jxigj3xh8 6dlx1oy18
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
a2u3jqb6nb5enpsqk
30 Jun 21
Submission of Matters to a Vote of Security Holders
12:00am
8-K
jsvm1vx00ml q1z7zzb
21 Jun 21
Other Events
4:04pm
8-K
yp17a074xl0p50e2cw
9 Jun 21
Other Events
4:40pm
8-K
ctyw41jn
4 Jun 21
POINT Biopharma Announces First Patients
4:22pm
8-K
bqrnfycn1ka
1 Jun 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
4:32pm
8-K
0bxogmw y5wo
28 Apr 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
5:13pm
8-K/A
ljsp1 ix2
18 Mar 21
Financial Statements and Exhibits
9:08am
8-K
hpnlj 6rqi2292ni6m
15 Mar 21
Public Investor Presentation Transcript
5:20pm
8-K
l2wzn 8qqciskr
15 Mar 21
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
8:19am
8-K
04ujkakf65rnixe
6 Aug 20
Other Events
10:36am
8-K
z5eda wrv6970svd8q
16 Jul 20
Report of Independent Registered Public Accounting Firm
4:30pm
8-K
n58mfbkwuxo16
10 Jul 20
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
5:17pm